Skip to content
MARKETS / BALCAO / CKDXF
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Opthea Ltd. CKDXF

7 fiscal years on record · USD · FY2024 reported · SEC filings only
$25,000
▼ 80.0% YoY
$-162.8M
$-158.7M
In brief

What this company does

The principal activity of Opthea Limited is to research and develop novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. Opthea's lead asset, sozinibercept, was being developed as a novel, first-in-class VEGF-C/D 'trap' inhibitor designed to be used in combination with standard-of-care anti-VEGF-A therapies to improve vision in wet AMD patients, many of whom respond sub-optimally or become refractory to existing therapies. In March 2025 the company announced the Phase 3 trials did not meet their primary endpoints. Since March of 2025 the company has been closing all clinical, manufacturing, and regulatory activities associated with the Wet AMD program and exiting all contracts related to the clinical trials.

Written from the business description in Opthea Limited's annual report to the U.S. Securities and Exchange Commission, filed 15 September 2025. Every sentence was checked against that document before publication.

Growth
USD 25,000.00
Revenue, FY2024 · full 7-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -162.8
-80M-160M2018201920202021202220232024
Compound annual growth
−34.9%
−15.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −15.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−651164 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -623048.0% · Net -651164.0%
-200000%-400000%-600000%2018201920202021202220232024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -158.7
-80M-160M2018201920202021202220232024

Total assetsUSD 56.8M
CashUSD 48.4M
Current ratio0.22×

Not available: we don't have the total debt figure for this period.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.2−0.2−0.2−0.1···
EBITDA $B·······
Income tax $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.2−0.2−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.2−0.2−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−0.13−0.35−0.32−0.26−0.14··
Dividend / sh $·······
Payout %−0−0−0−0−0··
ROE %·······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 50 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image